Toolbox resource: Overview of anti-CGRP clinical evidence in ‘difficult-to-treat’ migraine

Patients with migraine with inadequate response to prior preventive treatment illustrate one of the unmet needs in migraine standard-of-care. Clinical trials of monoclonal antibodies targeting the CGRP pathway have shown beneficial response in this ‘difficult-to-treat’ migraine patient population.^1,2,3